Investors interested in the biotechnology and pharmaceutical sectors frequently track several prominent neuroscience-focused stocks dedicated to developing treatments for central nervous system disorders, neurological diseases, and psychiatric conditions. Notable publicly traded companies in this specialized therapeutic arena include Biogen, Axsome Therapeutics, Intra-Cellular Therapies, Karuna Therapeutics (prior to its acquisition), and smaller clinical-stage enterprises like Minerva Neurosciences, all working on advanced therapeutics for complex brain-related medical conditions.